ERBB2 and small cell carcinoma: Posttreatment samples acquired secondary genetic alterations, including EGFR T790M, HER2 amplification, MET amplification, or small cell carcinoma transformation, but almost half of the samples did not show genetic abnormalities causing EGFR-TKI resistance (Figure S1).